[go: up one dir, main page]

CN102246045B - 用于检测和治疗脊柱和关节疼痛的生物标志物和方法 - Google Patents

用于检测和治疗脊柱和关节疼痛的生物标志物和方法 Download PDF

Info

Publication number
CN102246045B
CN102246045B CN200980149541.8A CN200980149541A CN102246045B CN 102246045 B CN102246045 B CN 102246045B CN 200980149541 A CN200980149541 A CN 200980149541A CN 102246045 B CN102246045 B CN 102246045B
Authority
CN
China
Prior art keywords
aggrecan
fibronectin
compound
pain
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980149541.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102246045A (zh
Inventor
盖塔诺·J·斯谷德瑞
刘易斯·S·汉纳
罗伯特·宝瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytonics Corp
Original Assignee
Cytonics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytonics Corp filed Critical Cytonics Corp
Publication of CN102246045A publication Critical patent/CN102246045A/zh
Application granted granted Critical
Publication of CN102246045B publication Critical patent/CN102246045B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
CN200980149541.8A 2008-10-16 2009-09-30 用于检测和治疗脊柱和关节疼痛的生物标志物和方法 Expired - Fee Related CN102246045B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10605908P 2008-10-16 2008-10-16
US61/106,059 2008-10-16
US11840108P 2008-11-26 2008-11-26
US61/118,401 2008-11-26
US12204508P 2008-12-12 2008-12-12
US61/122,045 2008-12-12
PCT/US2009/058976 WO2010045024A1 (fr) 2008-10-16 2009-09-30 Biomarqueurs et procédés pour la détection et le traitement d'une douleur spinale et articulaire

Publications (2)

Publication Number Publication Date
CN102246045A CN102246045A (zh) 2011-11-16
CN102246045B true CN102246045B (zh) 2014-04-02

Family

ID=41395058

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980149541.8A Expired - Fee Related CN102246045B (zh) 2008-10-16 2009-09-30 用于检测和治疗脊柱和关节疼痛的生物标志物和方法

Country Status (8)

Country Link
US (2) US8338572B2 (fr)
EP (1) EP2353012B1 (fr)
JP (1) JP2012505887A (fr)
KR (1) KR20110084254A (fr)
CN (1) CN102246045B (fr)
BR (1) BRPI0920582A2 (fr)
CA (1) CA2740871A1 (fr)
WO (1) WO2010045024A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2353012B1 (fr) 2008-10-16 2017-04-05 Cytonics Corporation Biomarqueurs et methodes servant a determiner et traiter les douleurs spinales et articulaires
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
GB2503131B (en) 2012-02-21 2015-11-18 Cytonics Corp Systems, compositions and methods for transplantation
WO2015031654A2 (fr) 2013-08-28 2015-03-05 Cytonics Corporation Systèmes, compositions et procédés de transplantation et de traitement d'états pathologiques
US10889631B2 (en) 2014-11-20 2021-01-12 Cytonics Corporation Therapeutic variant alpha-2-macroglobulin compositions
KR102070969B1 (ko) * 2018-04-10 2020-01-29 한국한의학연구원 통증 판별용 마커

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777437A (zh) * 2003-02-21 2006-05-24 Uab研究基金会 生物活性天然生物基质组合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5427954A (en) 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis
US5387504A (en) 1992-09-30 1995-02-07 Merck & Co., Inc. Monospecific antibodies and assay system for detecting stromelysin cleavage products
US5866007A (en) 1994-05-19 1999-02-02 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Method and apparatus for the collection, storage, and real time analysis of blood and other bodily fluids
US5935796A (en) 1995-06-30 1999-08-10 The University Of Melbourne Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown
US7285526B2 (en) 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
JPH10203999A (ja) * 1997-01-28 1998-08-04 Ajinomoto Co Inc 抗血栓剤
EP0998572A2 (fr) 1997-07-25 2000-05-10 Du Pont Pharmaceuticals Company Metalloproteases decomposant l'aggrecan
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
MXPA01005515A (es) 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
US6656745B1 (en) 2000-06-02 2003-12-02 Francis X. Cole Devices and methods for a multi-level, semi-quantitative immunodiffusion assay
JP3800175B2 (ja) 2000-12-18 2006-07-26 アステラス製薬株式会社 新規なアグリカナーゼ
DE10127572A1 (de) 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
CN1324778C (zh) * 2001-11-27 2007-07-04 株式会社藤仓 用于电力电缆电性连接的构造和部件及该部件的制造方法
US20040115629A1 (en) 2002-01-09 2004-06-17 Panzer Scott R Molecules for diagnostics and therapeutics
US20050152905A1 (en) 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
AU2003287697A1 (en) 2002-11-08 2004-06-03 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
JP2004256436A (ja) * 2003-02-26 2004-09-16 Keio Gijuku アグリカナーゼ−１阻害剤
US20060188885A1 (en) 2003-04-18 2006-08-24 Bodian Dale L High throughput functional genomic screening methods for osteoarthritis
US7183930B2 (en) 2003-07-18 2007-02-27 Intelligent Mechatronic Systems Inc. Occupant heartbeat detection and monitoring system
JP2008507255A (ja) 2004-03-12 2008-03-13 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
AU2004323001A1 (en) 2004-09-09 2006-03-16 Agency For Science, Technology And Research Process for isolating biomaterial from tissue and an isolated biomaterial extract prepared therefrom
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007045661A1 (fr) * 2005-10-20 2007-04-26 Nordic Bioscience Diagnostics A/S Détection ou quantification d'aggrecane et de fragments de celui-ci
US20070099246A1 (en) 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
EP2353012B1 (fr) 2008-10-16 2017-04-05 Cytonics Corporation Biomarqueurs et methodes servant a determiner et traiter les douleurs spinales et articulaires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777437A (zh) * 2003-02-21 2006-05-24 Uab研究基金会 生物活性天然生物基质组合物

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
A.Struglics Ph.D.
Barilla M-L, et al.Fibronectin fragments and their role in inflammatory arthritis.《Seminars in arthritis and rheumatism》.2000,第29卷(第4期),252-265.
Fibronectin fragments and their role in inflammatory arthritis;Barilla M-L, et al;《Seminars in arthritis and rheumatism》;20000201;第29卷(第4期);252-265 *
Heather F Bigg, et al.The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis.《Current Opinion in Pharmacology》.2001,(第1期),314-320.
Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments;A. Struglics, Ph.D.,et al;《Osteoarthritis and Cartilage》;20060201;第14卷(第2期);101-113 *
Poster 108:Characterization of fibronectin fragments in human surgical intervertebral disk specimens;Zhang, et al;《Archives of physical medicine and rehabilitation, W. B. 》;20070901;第88卷(第9期);E40 *
Rheumatism》.2006,第54卷(第9期),2912-2922. *
The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis;Heather F Bigg, et al;《Current Opinion in Pharmacology》;20011231(第1期);摘要，第316页左栏第9行至318页左栏第6行 *
Zack Marc D,et al.Identification of fibronectin neoepitopes present in human osteoarthritic cartilage.《Arthritis & Rheumatism》.2006,第54卷(第9期),2912-2922.
Zack Marc D,et al.Identification of fibronectin neoepitopes present in human osteoarthritic cartilage.《Arthritis &amp *
Zhang et al.Poster 108:Characterization of fibronectin fragments in human surgical intervertebral disk specimens.《Archives of physical medicine and rehabilitation

Also Published As

Publication number Publication date
US20100098684A1 (en) 2010-04-22
US8841079B2 (en) 2014-09-23
US8338572B2 (en) 2012-12-25
EP2353012A1 (fr) 2011-08-10
JP2012505887A (ja) 2012-03-08
CN102246045A (zh) 2011-11-16
EP2353012B1 (fr) 2017-04-05
CA2740871A1 (fr) 2010-04-22
KR20110084254A (ko) 2011-07-21
BRPI0920582A2 (pt) 2019-08-27
WO2010045024A1 (fr) 2010-04-22
US20130078246A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
Mall et al. Factors affecting rotator cuff healing
Taniguchi et al. Intra-articular platelet-rich plasma (PRP) injections for treating knee pain associated with osteoarthritis of the knee in the Japanese population: a phase I and IIa clinical trial
Saxler et al. Localization of SP-and CGRP-immunopositive nerve fibers in the hip joint of patients with painful osteoarthritis and of patients with painless failed total hip arthroplasties
CN102246045B (zh) 用于检测和治疗脊柱和关节疼痛的生物标志物和方法
Kapoor et al. Osteoarthritis: Pathogenesis, diagnosis, available treatments, drug safety, regenerative and precision medicine
Ulivi et al. Micro-fragmented adipose tissue (mFAT) associated with arthroscopic debridement provides functional improvement in knee osteoarthritis: a randomized controlled trial
Koeck et al. Predominance of synovial sensory nerve fibers in arthrofibrosis following total knee arthroplasty compared to osteoarthritis of the knee
LaFrance et al. The effect of platelet enriched plasma on clinical outcomes in patients with femoroacetabular impingement following arthroscopic labral repair and femoral neck osteoplasty
Yang et al. Effect of combined sex hormone replacement on bone/cartilage turnover in a murine model of osteoarthritis
Boesmueller et al. Neurofilament distribution in the superior labrum and the long head of the biceps tendon
JP2012505887A5 (fr)
Kraus et al. Molecular biomarker approaches to prevention of post-traumatic osteoarthritis
Zanotto et al. Microfracture augmentation with trypsin pretreatment and growth factor–functionalized self-assembling peptide hydrogel scaffold in an equine model
CN102239411B (zh) 通过使用gi蛋白受体来分类和诊断脊柱侧凸的方法
Staszkiewicz et al. Usefulness of detecting brain-derived neurotrophic factor in intervertebral disc degeneration of the lumbosacral spine
Johnson et al. Cartilage-derived biomarkers of osteoarthritis in synovial fluid of dogs with naturally acquired rupture of the cranial cruciate ligament
Gabusi et al. Cartilage and bone serum biomarkers as novel tools for monitoring knee osteochondritis dissecans treated with osteochondral scaffold
Cheng et al. Complement C3-α and C3-β Levels in Synovial Fluid But Not in Blood Correlate With the Severity of Osteoarthritis Research Society International Histopathological Grades in Primary Knee Osteoarthritis
Røren Nordén et al. Reduced appendicular lean body mass, muscle strength, and size of type II muscle fibers in patients with spondyloarthritis versus healthy controls: a cross‐sectional study
Kondhalkar et al. Determination of Clinical Utility of Novel Biochemical Markers in Osteoarthritis
Anderson et al. Fibronectin splicing variants in human intervertebral disc and association with disc degeneration
Jordan Cartilage oligomeric matrix protein as a marker of osteoarthritis
Colombini et al. Treatment with CR500® improves algofunctional scores in patients with knee osteoarthritis: A post-market confirmatory interventional, single arm clinical investigation
Chen et al. Continuous mechanical compression-induced intervertebral disc degeneration and pain in the caudal spine in rats
Anwar et al. Validation of Levels of Decorin as A Reliable Biomarker of Osteoarthritis: Comparison of Serum and Synovial Fluid Levels

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140402

Termination date: 20160930

CF01 Termination of patent right due to non-payment of annual fee